|Dr. Patrik De Haes ViBio, BVBA, M.D.||Chief Exec. Officer and Exec. Director||586.48k||N/A||N/A|
|Mr. Paul G. Howes||Exec. Director and Exec. Chairman of Thrombogenics Inc||23.27k||N/A||63|
|Mr. Dominique Vanfleteren||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Wouter Piepers||Global Head of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Claude Sander||Chief Legal Officer, Corp. Compliance Officer and Sec.||N/A||N/A||N/A|
ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The companys lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.
ThromboGenics NV’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.